As a prescription medication used to treat adults and children 12 years and older with psoriasis or other certain skin conditions that cause red, flaky, and itchy skin, Clobetasol propionate, CAS number 25122-56-7, is effective and safe. Known as the brand name Olux, which is marketed by Stiefel Laboratories, clobetasol propionate has a patent expiration of March 1, 2016. Clobetasol propionate is available as a topical steroid emollient foam or as a regular foam. It is effectual by decreasing inflammation and suppressing an overactive immune system, which is thought to contribute to psoriasis. LGM Pharma provides clobetasol propionate as a TEVA API product, CAS number 25122-41-2, and offers complete support to clients throughout the research and development process.
Derived from the Greek word psora, meaning “itch”, clobetasol propionate successfully relieves one of the most troubling symptoms of psoriasis-itching. While patients stricken with psoriasis are stressed due to their outward appearance of psoriasis, particularly when it is visible on their face and hands, many more patients complain of itchiness being the symptom they have a hard time dealing with. With 7.5 million Americans estimated to have psoriasis, the use of safe and efficacious medications like clobetasol propionate is essential for this large patient population. Depression is often a symptom spawned from psoriasis as well. A study conducted by the University of Pennsylvania, indicated that psoriasis patients had a 39% increase in the risk of the clinical diagnosis of depression. In addition, psoriasis patients had a 44% increase in the risk of suicidal tendencies. Topical treatments like clobetasol propionate should be considered by practitioners alongside medical or therapeutic treatment for depression, if needed, for patients with psoriasis on a regular basis.
The regular foam clobetasol propionate contains alcohol and can be somewhat drying for patients. The emollient foam offered of clobetasol propionate is alcohol-free and is less drying. The emollient form of clobetasol propionate should not be used for longer than 2 weeks in a row, or more than 50 grams (21 capfuls) in one week. This extremely potent topical corticosteroid will result in a significant decrease in skin inflammation, redness, swelling, burning, itching, and irritation of the scalp, as well as psoriasis. Clobetasol propionate should not be used by children under age 12, or women who are pregnant, may be pregnant or are breastfeeding.
One well-controlled clinical study of clobetasol propionate evaluated 188 patients who had moderate to severe scalp psoriasis. These patients were treated twice daily for 2 weeks with one of four treatments: OLUX Foam, Vehicle foam, a commercially available clobetasol propionate solution (Temovate Scalp Application), or Vehicle solution. The efficacy of OLUX Foam, or clobetasol propionate foam, in treating scalp psoriasis at the end of the 2 week treatment was clearly superior when compared to the 3 aforementioned treatments. With a limited selection of medications to treat scalp psoriasis, as well as other forms of psoriasis- like skin conditions, the advent of new treatments and generic options for established medications is important and advantageous for researchers, practitioners and especially patients.
Products for R&D use in accordance with 35 USC 271(e)+A13(1). Any patent infringement and resulting liability is solely at buyer risk.